Evin Bozcali1, Veli Polat2, Gonul Aciksari3, Selcuk Opan3, Ibrahim Halil Bayrak3, Nurcan Paker4, Osman Karakaya3. 1. Department of Cardiology, Koç University School of Medicine, Istanbul, Turkey. 2. Department of Cardiology, Bakirkoy Dr. Sadi Konuk Education and Research Hospital, Istanbul, Turkey. Electronic address: dr.velipolat@gmail.com. 3. Department of Cardiology, Bakirkoy Dr. Sadi Konuk Education and Research Hospital, Istanbul, Turkey. 4. Duzen Laboratory, Cemal Sahir Sok. No. 14, 34383, Mecidiyekoy, Istanbul, Turkey.
Abstract
OBJECTIVE: Microvascular dysfunction has been reported in cardiac syndrome X (CSX), even though the underlying mechanisms still remain uncertain. Galectin-3 has been recently recognized as a biomarker of cardiovascular fibrosis and inflammation. We sought to investigate the role of galectin-3 in the CSX. METHODS: We studied 115 consecutive CSX patients (mean age 55.43 ± 8.71 years, 36 men) and 74 healthy controls (mean age 54.53 ± 10.07 years, 31 men). Serum concentrations of galectin-3 and high-sensitive C-reactive protein (hs-CRP) were measured on the blood samples. RESULTS: Galectin-3 concentrations were significantly higher in patients with CSX compared to controls (0.90 ng/ml; IQR, 0.40-1.70 ng/ml vs 0.40 ng/ml; IQR, 0.36-0.44 ng/ml, p < 0.0001). Although, the prevalence of diabetes mellitus, hypertension and family history of coronary artery disease (CAD) were significantly higher among patients with CSX, following adjustment for diabetes mellitus, hypertension, and family history of CAD, serum galectin-3 concentrations were still found significantly increased in patients with CSX. Galectin-3 concentrations correlated positively with hs-CRP (r = 0.16, p = 0.03). In addition, concentrations of galectin-3, hs-CRP, fasting glucose, uric acid and family history of CAD were determined as independent predictors of the CSX. CONCLUSION: It was found that galectin-3 serum concentrations are higher in patients with CSX compared to healthy controls. Further studies on larger population are needed to confirm the relation between the fibrosis and the CSX, as well as to explore the potential role of galectin-3 in the CSX.
OBJECTIVE:Microvascular dysfunction has been reported in cardiac syndrome X (CSX), even though the underlying mechanisms still remain uncertain. Galectin-3 has been recently recognized as a biomarker of cardiovascular fibrosis and inflammation. We sought to investigate the role of galectin-3 in the CSX. METHODS: We studied 115 consecutive CSXpatients (mean age 55.43 ± 8.71 years, 36 men) and 74 healthy controls (mean age 54.53 ± 10.07 years, 31 men). Serum concentrations of galectin-3 and high-sensitive C-reactive protein (hs-CRP) were measured on the blood samples. RESULTS:Galectin-3 concentrations were significantly higher in patients with CSX compared to controls (0.90 ng/ml; IQR, 0.40-1.70 ng/ml vs 0.40 ng/ml; IQR, 0.36-0.44 ng/ml, p < 0.0001). Although, the prevalence of diabetes mellitus, hypertension and family history of coronary artery disease (CAD) were significantly higher among patients with CSX, following adjustment for diabetes mellitus, hypertension, and family history of CAD, serum galectin-3 concentrations were still found significantly increased in patients with CSX. Galectin-3 concentrations correlated positively with hs-CRP (r = 0.16, p = 0.03). In addition, concentrations of galectin-3, hs-CRP, fasting glucose, uric acid and family history of CAD were determined as independent predictors of the CSX. CONCLUSION: It was found that galectin-3 serum concentrations are higher in patients with CSX compared to healthy controls. Further studies on larger population are needed to confirm the relation between the fibrosis and the CSX, as well as to explore the potential role of galectin-3 in the CSX.
Authors: Germán E González; N-E Rhaleb; Martin A D'Ambrosio; Pablo Nakagawa; Tang-Dong Liao; Edward L Peterson; Pablo Leung; Xiangguo Dai; Branislava Janic; Yun-He Liu; Xiao-Ping Yang; Oscar A Carretero Journal: Am J Physiol Heart Circ Physiol Date: 2016-08-05 Impact factor: 4.733
Authors: S C Efe; K Demirci; S Ozturk; A S Gurbuz; N Poci; A Kilicgedik; A Guler; M F Yilmaz; I A İzgi; C Kirma Journal: Herz Date: 2017-06-06 Impact factor: 1.443
Authors: Alexander R Opotowsky; Fernando Baraona; Justin Owumi; Brittani Loukas; Michael N Singh; Anne Marie Valente; Fred Wu; Susan Cheng; Gruschen Veldtman; Eric B Rimm; Michael J Landzberg Journal: J Am Heart Assoc Date: 2016-01-11 Impact factor: 5.501
Authors: Jakob Schroder; Naja Dam Mygind; Daria Frestad; Marie Michelsen; Hannah Elena Suhrs; Kira Bang Bove; Ida Gustafsson; Jens Kastrup; Eva Prescott Journal: Int J Cardiol Heart Vasc Date: 2019-05-30
Authors: Salvatore Sciacchitano; Luca Lavra; Alessandra Morgante; Alessandra Ulivieri; Fiorenza Magi; Gian Paolo De Francesco; Carlo Bellotti; Leila B Salehi; Alberto Ricci Journal: Int J Mol Sci Date: 2018-01-26 Impact factor: 5.923
Authors: Anand Venkatraman; Peter Callas; Leslie A McClure; Fred Unverzagt; Garima Arora; Virginia Howard; Virginia G Wadley; Mary Cushman; Pankaj Arora Journal: Alzheimers Dement (N Y) Date: 2018-04-26